Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 2/2018

01-02-2018 | Nephrology - Review

Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies

Authors: Wei Pan, Yongbo Kang

Published in: International Urology and Nephrology | Issue 2/2018

Login to get access

Abstract

The complicated communities of microbiota colonizing the human gastrointestinal tract exert a strong function in health maintenance and disease prevention. Indeed, accumulating evidence has indicated that the intestinal microbiota plays a key role in the pathogenesis and development of chronic kidney disease (CKD). Modulation of the gut microbiome composition in CKD may contribute to the accumulation of gut-derived uremic toxins, high circulating level of lipopolysaccharides and immune deregulation, all of which play a critical role in the pathogenesis of CKD and CKD-associated complications. In this review, we discuss the recent findings on the potential impact of gut microbiota in CKD and the underlying mechanisms by which microbiota can influence kidney diseases and vice versa. Additionally, the potential efficacy of pre-, pro- and synbiotics in the restoration of healthy gut microbia is described in detail to provide future directions for research.
Literature
1.
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382(9889):339–352PubMedCrossRef
2.
Evenepoel P, Meijers BK, Bammens BR et al (2009) Uremic toxins originating from colonic microbial metabolism. Kidney Int 76:S12–S19CrossRef
3.
Anders H-J, Andersen K, Stecher B (2013) The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 83(6):1010–1016PubMedCrossRef
4.
Szeto C-C, Kwan BC-H, Chow K-M et al (2008) Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 3(2):431–436PubMedPubMedCentralCrossRef
5.
Housman A, Shropshire Lad A Incidence and prevalence. United States Renal Data System. In: Proceedings of the 2010 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States, vol 2. Atlas of ESRD
6.
Cerf-Bensussan N, Eberl G (2012) The dialog between microbiota and the immune system: shaping the partners through development and evolution. Semin Immunol 24(1):1–2PubMedCrossRef
7.
Gonçalves S, Pecoits-Filho R, Perreto S et al (2006) Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transplant 21(10):2788–2794PubMedCrossRef
8.
Le Chatelier E, Nielsen T, Qin J et al (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500(7464):541–546PubMedCrossRef
9.
Cani PD, Delzenne NM (2009) The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 15(13):1546–1558PubMedCrossRef
10.
Vaziri ND (2012) CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens 21(6):587PubMedPubMedCentralCrossRef
11.
Bäckhed F, Ley RE, Sonnenburg JL et al (2005) Host-bacterial mutualism in the human intestine. Science 307(5717):1915–1920PubMedCrossRef
12.
Hooper LV, Midtvedt T, Gordon JI (2002) How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr 22(1):283–307PubMedCrossRef
13.
Ley RE, Turnbaugh PJ, Klein S et al (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444(7122):1022PubMedCrossRef
14.
15.
16.
Hida M, Aiba Y, Sawamura S et al (1996) Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin®, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 74(2):349–355PubMedCrossRef
17.
Simenhoff M, Dunn S, Zollner G et al (1995) Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab 22(1–3):92–96
18.
Vaziri ND, Wong J, Pahl M et al (2013) Chronic kidney disease alters intestinal microbial flora. Kidney Int 83(2):308–315PubMedCrossRef
19.
Aron-Wisnewsky J, Clément K (2016) The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nat Rev Nephrol 12(3):169–181PubMedCrossRef
20.
Mafra D, Lobo JC, Barros AF et al (2014) Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease. Future Microbiol 9(3):399–410PubMedCrossRef
21.
Sabatino A, Regolisti G, Brusasco I et al (2015) Alterations of intestinal barrier and microbiota in chronic kidney disease. Nephrol Dial Transplant 30(6):924–933PubMedCrossRef
22.
Carrero JJ, Stenvinkel P (2009) Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 4(Supplement 1):S49–S55PubMedCrossRef
23.
Neirynck N, Vanholder R, Schepers E et al (2013) An update on uremic toxins. Int Urol Nephrol 45(1):139–150PubMedCrossRef
24.
Sirich TL, Funk BA, Plummer NS et al (2014) Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion. J Am Soc Nephrol 25(3):615–622PubMedCrossRef
25.
Soulage CO, Koppe L, Fouque D (2013) Protein-bound uremic toxins… new targets to prevent insulin resistance and dysmetabolism in patients with chronic kidney disease. J Ren Nutr 23(6):464–466PubMedCrossRef
26.
Hughes R, Magee E, Bingham S (2000) Protein degradation in the large intestine: relevance to colorectal cancer. Curr Issues Intest Microbiol 1(2):51–58PubMed
27.
Meijers BK, Verbeke K, Dehaen W et al (2009) The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 54(5):891–901PubMedCrossRef
28.
Meijers BK, Claes K, Bammens B et al (2010) p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 5(7):1182–1189PubMedPubMedCentralCrossRef
29.
Koppe L, Pillon NJ, Vella RE et al (2013) p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol 24(1):88–99PubMedCrossRef
30.
Mutsaers HA, Stribos EG, Glorieux G et al (2015) Chronic kidney disease and fibrosis: the role of uremic retention solutes. Front Med 2:60CrossRef
31.
Meijers BK, Evenepoel P (2011) The gut–kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant 26(3):759–761PubMedCrossRef
32.
Barreto FC, Barreto DV, Liabeuf S et al (2009) Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 4(10):1551–1558PubMedPubMedCentralCrossRef
33.
Raff AC, Meyer TW, Hostetter TH (2008) New insights into uremic toxicity. Curr Opin Nephrol Hypertens 17(6):560–565PubMedCrossRef
34.
Faure V, Dou L, Sabatier F et al (2006) Elevation of circulating endothelial microparticles in patients with chronic renal failure. J Thromb Haemost 4(3):566–573PubMedCrossRef
35.
Tumur Z, Shimizu H, Enomoto A et al (2010) Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-ĸB activation. Am J Nephrol 31(5):435–441PubMedCrossRef
36.
Lekawanvijit S, Adrahtas A, Kelly DJ et al (2010) Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 31(14):1771–1779PubMedCrossRef
37.
Aoki K, Teshima Y, Kondo H et al (2015) Role of indoxyl sulfate as a predisposing factor for atrial fibrillation in renal dysfunction. J Am Heart Assoc 4(10):e002023PubMedPubMedCentralCrossRef
38.
Gross P, Massy ZA, Henaut L et al (2015) Para-cresyl sulfate acutely impairs vascular reactivity and induces vascular remodeling. J Cell Physiol 230(12):2927–2935PubMedCrossRef
39.
Lin C-J, Pan C-F, Liu H-L et al (2012) The role of protein-bound uremic toxins on peripheral artery disease and vascular access failure in patients on hemodialysis. Atherosclerosis 225(1):173–179PubMedCrossRef
40.
Lin C-J, Wu V, Wu P-C et al (2015) Meta-analysis of the associations of p-cresyl sulfate (PCS) and indoxyl sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure. PLoS ONE 10(7):e0132589PubMedPubMedCentralCrossRef
41.
Nii-Kono T, Iwasaki Y, Uchida M et al (2007) Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 71(8):738–743PubMedCrossRef
42.
Lin C-J, Pan C-F, Chuang C-K et al (2014) Association of indoxyl sulfate with fibroblast growth factor 23 in patients with advanced chronic kidney disease. Am J Med Sci 347(5):370–376PubMedCrossRef
43.
Hirata J, Hirai K, Asai H et al (2015) Indoxyl sulfate exacerbates low bone turnover induced by parathyroidectomy in young adult rats. Bone 79:252–258PubMedCrossRef
44.
Howitt MR, Garrett WS (2012) A complex microworld in the gut: gut microbiota and cardiovascular disease connectivity. Nat Med 18(8):1188–1189PubMedCrossRef
45.
Koeth RA, Wang Z, Levison BS et al (2013) Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19(5):576–585PubMedPubMedCentralCrossRef
46.
Rak K, Rader DJ (2011) Cardiovascular disease: the diet-microbe morbid union. Nature 472(7341):40–41PubMedCrossRef
47.
Stubbs JR, House JA, Ocque AJ et al (2016) Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J Am Soc Nephrol 27(1):305–313PubMedCrossRef
48.
Missailidis C, Hällqvist J, Qureshi AR et al (2016) Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease. PLoS ONE 11(1):e0141738PubMedPubMedCentralCrossRef
49.
Kaysen GA, Johansen KL, Chertow GM et al (2015) Associations of trimethylamine N-oxide with nutritional and inflammatory biomarkers and cardiovascular outcomes in patients new to dialysis. J Ren Nutr 25(4):351–356PubMedPubMedCentralCrossRef
50.
Saito A, Takagi T, Chung T et al (1983) Serum levels of polyamines in patients with chronic renal failure. Kidney Int 16:S234–S237
51.
Lutz W (1979) A uremic peptide containing polyamine: formation and possible role in uremic hypertriglyceridemia. Physiol Chem Phys 12(5):451–456
52.
Chiang C-K, Tanaka T, Inagi R et al (2011) Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Investig 91(11):1564–1571PubMedCrossRef
53.
Nangaku M, Mimura I, Yamaguchi J et al (2015) Role of uremic toxins in erythropoiesis-stimulating agent resistance in chronic kidney disease and dialysis patients. J Ren Nutr 25(2):160–163PubMedCrossRef
54.
55.
Yoshida K, Yoneda T, Kimura S et al (2006) Polyamines as an inhibitor on erythropoiesis of hemodialysis patients by in vitro bioassay using the fetal mouse liver assay. Ther Apheresis Dial 10(3):267–272CrossRef
56.
Cario E, Gerken G, Podolsky D (2007) Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 132(4):1359–1374PubMedCrossRef
57.
58.
Kiechl S, Lorenz E, Reindl M et al (2002) Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347(3):185–192PubMedCrossRef
59.
Muccioli GG, Naslain D, Bäckhed F et al (2010) The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 6(1):392PubMedPubMedCentral
60.
Sivapalaratnam S, Farrugia R, Nieuwdorp M et al (2011) Identification of candidate genes linking systemic inflammation to atherosclerosis; results of a human in vivo LPS infusion study. BMC Med Genomics 4(1):64PubMedPubMedCentralCrossRef
61.
Ryu M, Kulkarni OP, Radomska E et al (2011) Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-α-mediated podocyte loss. Kidney Int 79(2):189–198PubMedCrossRef
62.
Patole PS, Pawar RD, Lichtnekert J et al (2007) Coactivation of Toll-like receptor-3 and -7 in immune complex glomerulonephritis. J Autoimmun 29(1):52–59PubMedCrossRef
63.
Farhadi A, Banan A, Fields J et al (2003) Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol 18(5):479–497PubMedCrossRef
64.
Magnusson M, Magnusson K-E, Sundqvist T et al (1990) Increased intestinal permeability to differently sized polyethylene glycols in uremic rats: effects of low-and high-protein diets. Nephron 56(3):306–311PubMedCrossRef
65.
Magnusson M, Magnusson K, Sundqvist T et al (1991) Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 32(7):754–759PubMedPubMedCentralCrossRef
66.
67.
de Almeida Duarte JB, de Aguilar-Nascimento JE, Nascimento M et al (2004) Bacterial translocation in experimental uremia. Urol Res 32(4):266–270PubMedCrossRef
68.
Vaziri ND, Yuan J, Nazertehrani S et al (2013) Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol 38(2):99–103PubMedCrossRef
69.
Vaziri N, Dure-Smith B, Miller R et al (1985) Pathology of gastrointestinal tract in chronic hemodialysis patients: an autopsy study of 78 cases. Am J Gastroenterol 80(8):608–611PubMed
70.
71.
Wang F, Zhang P, Jiang H et al (2012) Gut bacterial translocation contributes to microinflammation in experimental uremia. Dig Dis Sci 57(11):2856–2862PubMedCrossRef
72.
Wang F, Jiang H, Shi K et al (2012) Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrology 17(8):733–738PubMedCrossRef
73.
74.
Bromberg JS, Fricke WF, Brinkman CC et al (2015) Microbiota [mdash] implications for immunity and transplantation. Nat Rev Nephrol 11(6):342–353PubMedCrossRef
75.
Stenvinkel P (2005) Inflammation in end-stage renal disease–a fire that burns within. Contrib Nephrol 149:185–199PubMedCrossRef
76.
77.
Stearns-Kurosawa DJ, Osuchowski MF, Valentine C et al (2011) The pathogenesis of sepsis. Annu Rev Pathol Mech Dis 6:19–48CrossRef
78.
Carrero JJ, Stenvinkel P (2010) Inflammation in end-stage renal disease—What have we learned in 10 years? Semin Dial 23(5):498–509PubMedCrossRef
79.
Harris K, Kassis A, Major G et al (2012) Is the gut microbiota a new factor contributing to obesity and its metabolic disorders? J Obes 2012:879151PubMedPubMedCentral
80.
81.
82.
83.
Macpherson AJ, Harris NL (2004) Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 4(6):478–485PubMedCrossRef
84.
Kranich J, Maslowski KM, Mackay CR (2011) Commensal flora and the regulation of inflammatory and autoimmune responses. Semin Immunol 23(2):139–145PubMedCrossRef
85.
Niebauer J, Volk H-D, Kemp M et al (1999) Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353(9167):1838–1842PubMedCrossRef
86.
McIntyre CW, Harrison LE, Eldehni MT et al (2011) Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 6(1):133–141PubMedPubMedCentralCrossRef
87.
Lee YK, Menezes JS, Umesaki Y et al (2011) Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci 108(Supplement 1):4615–4622PubMedCrossRef
88.
89.
Janus N, Vacher L-V, Karie S et al (2008) Vaccination and chronic kidney disease. Nephrol Dial Transplant 23(3):800–807PubMedCrossRef
90.
91.
Mutsaers HA, Engelke UF, Wilmer MJ et al (2013) Optimized metabolomic approach to identify uremic solutes in plasma of stage 3–4 chronic kidney disease patients. PLoS ONE 8(8):e71199PubMedPubMedCentralCrossRef
92.
Konstantinov SR, Smidt H, de Vos WM et al (2008) S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. Proc Natl Acad Sci 105(49):19474–19479PubMedPubMedCentralCrossRef
93.
Van Baarlen P, Troost FJ, van Hemert S et al (2009) Differential NF-κB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc Natl Acad Sci 106(7):2371–2376PubMedPubMedCentralCrossRef
94.
Murthy M, Venkitanarayan K, Rangavajhyala N et al (2000) Delineation of beneficial characteristics of effective probiotics. JAMA 3(2):38–43
95.
Chen L, Liu W, Li Y et al (2013) Lactobacillus acidophilus ATCC 4356 attenuates the atherosclerotic progression through modulation of oxidative stress and inflammatory process. Int Immunopharmacol 17(1):108–115PubMedCrossRef
96.
Ranganathan N, Patel B, Ranganathan P et al (2005) Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats. Sci World J 5:652–660CrossRef
97.
Ranganathan N, Patel BG, Ranganathan P et al (2006) In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease. ASAIO J 52(1):70–79PubMedCrossRef
98.
Niwa T (2011) Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Ther Apheresis Dial 15(2):120–124CrossRef
99.
Ueda H, Shibahara N, Takagi S et al (2008) AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail 30(9):856–860PubMedCrossRef
100.
Takayama F, Taki K, Niwa T (2003) Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis 41(3):S142–S145PubMedCrossRef
101.
Taki K, Takayama F, Niwa T (2005) Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J Ren Nutr 15(1):77–80PubMedCrossRef
102.
Piñero-Lambea C, Ruano-Gallego D, Fernández LÁ (2015) Engineered bacteria as therapeutic agents. Curr Opin Biotechnol 35:94–102PubMedCrossRef
103.
104.
Gibson GR, Roberfroid MB (1995) Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 125(6):1401PubMed
105.
Gibson GR, Probert HM, Van Loo J et al (2004) Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 17(02):259–275PubMedCrossRef
106.
Silk D, Davis A, Vulevic J et al (2009) Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 29(5):508–518PubMedCrossRef
107.
Meijers BK, De Preter V, Verbeke K et al (2010) p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 25(1):219–224PubMedCrossRef
108.
Salmean YA, Segal MS, Langkamp-Henken B et al (2013) Foods with added fiber lower serum creatinine levels in patients with chronic kidney disease. J Ren Nutr 23(2):e29–e32PubMedCrossRef
109.
Cani PD, Neyrinck A, Fava F et al (2007) Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50(11):2374–2383PubMedCrossRef
110.
Broekaert WF, Courtin CM, Verbeke K et al (2011) Prebiotic and other health-related effects of cereal-derived arabinoxylans, arabinoxylan-oligosaccharides, and xylooligosaccharides. Crit Rev Food Sci Nutr 51(2):178–194PubMedCrossRef
111.
Gibson GR, Beatty ER, Wang X et al (1995) Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 108(4):975–982PubMedCrossRef
112.
Pylkas AM, Juneja LR, Slavin JL (2005) Comparison of different fibers for in vitro production of short chain fatty acids by intestinal microflora. J Med Food 8(1):113–116PubMedCrossRef
113.
Reimer R, McBURNEY MI (1996) Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats. Endocrinology 137(9):3948–3956PubMedCrossRef
114.
Dumoulin V, Moro F, Barcelo A et al (1998) Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum. Endocrinology 139(9):3780–3786PubMedCrossRef
115.
116.
117.
Batterham RL, Cowley MA, Small CJ et al (2002) Gut hormone PYY3-36 physiologically inhibits food intake. Nature 418(6898):650PubMedCrossRef
118.
Delzenne NM, Cani PD, Daubioul C et al (2005) Impact of inulin and oligofructose on gastrointestinal peptides. Br J Nutr 93(S1):S157–S161PubMedCrossRef
119.
Alimentarius C (2010) Guidelines on nutrition labelling CAC/GL 2-1985 as last amended 2010. Joint FAO/WHO Food Standards Programme, Secretariat of the Codex Alimentarius Commission, FAO, Rome
120.
Chiavaroli L, Mirrahimi A, Sievenpiper J et al (2015) Dietary fiber effects in chronic kidney disease: a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr 69(7):761PubMedCrossRef
121.
Vaziri ND, Liu S-M, Lau WL et al (2014) High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS ONE 9(12):e114881PubMedPubMedCentralCrossRef
122.
Sirich TL, Plummer NS, Gardner CD et al (2014) Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients. Clin J Am Soc Nephrol 9(9):1603–1610PubMedPubMedCentralCrossRef
123.
Evenepoel P, Bammens B, Verbeke K et al (2006) Acarbose treatment lowers generation and serum concentrations of the protein-bound solute p-cresol: a pilot study. Kidney Int 70(1):192–198PubMedCrossRef
124.
Rossi M, Johnson DW, Morrison M et al (2016) Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial. Clin J Am Soc Nephrol 11(2):223–231PubMedPubMedCentralCrossRef
125.
Nakabayashi I, Nakamura M, Kawakami K et al (2011) Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transplant 26(3):1094–1098PubMedCrossRef
Metadata
Title
Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies
Authors
Wei Pan
Yongbo Kang
Publication date
01-02-2018
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2018
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-017-1689-5

Other articles of this Issue 2/2018

International Urology and Nephrology 2/2018 Go to the issue

Nephrology - Letter to the editor

What is the place of POEMS syndrome in the current classification of monoclonal gammopathies of renal significance?

Nephrology - Original Paper

Association of ALOX12 gene polymorphism with all-cause and cardiovascular mortality in diabetic nephropathy

Urology - Original Paper

Anticancer activity of Schiff base–Poloxamer P85 combination against kidney cancer

Urology - Original Paper

Pathological upstaging of clinical T1 renal cell carcinoma: an analysis of 115,835 patients from National Cancer Data Base, 2004–2013

Urology - Original Paper

Risk factors for failed urethrocutaneous fistula repair after transverse preputial island flap urethroplasty in pediatric hypospadias

Nephrology - Original Paper

Clinicopathological study of male and female patients with lupus nephritis: a retrospective study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits